Alector, Inc. — FY 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. Alector is a clinical-stage biopharmaceutical company developing immuno-neurology therapies. It had no approved products and generated no product-sale revenue; reported revenue came from collaborations and a grant.
Financial results and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Collaboration revenue | $207.1 million | $21.1 million |
| Research and development expense | $189.4 million | $156.9 million |
| General and administrative expense | $55.0 million | $59.4 million |
| Operating loss | $37.4 million | $195.2 million |
| Net loss | $36.3 million | $190.2 million |
| Basic and diluted net loss per share | $0.45 | $2.45 |
| Cash provided by (used in) operating activities | $298.6 million | $(166.7) million |
Revenue rose primarily because Alector recognized $173.4 million for the AL001 FTD-GRN license under its GSK agreement. The improvement in net loss largely reflects collaboration revenue, not product sales. R&D expense increased 21%; G&A declined mainly because 2020 included higher arbitration-related legal costs. Gross margin is not applicable to this development-stage business.
At year-end, cash and cash equivalents were $329.2 million and marketable securities were $406.1 million, totaling $735.3 million. Current assets were $749.7 million versus current liabilities of $139.6 million. The filing reports no borrowings; liabilities include $425.2 million of deferred revenue and $47.6 million of operating lease liabilities. Management estimated funding into mid-2024, including the $200 million GSK payment received in January 2022. This estimate depends on operating assumptions and may change.
Operating cash flow benefited from a $292.9 million increase in deferred revenue tied mainly to GSK’s upfront payment; it should not be read as recurring operating cash generation. Investing activities used $49.7 million, primarily reflecting net purchases of marketable securities; financing activities provided $30.3 million, primarily from option exercises. A 100-basis-point rate change was estimated to change investment fair value by approximately $3.6 million.
Material changes and collaboration economics
- In 2021, Alector entered a global development and commercialization collaboration with GSK for AL001 and AL101. The $700 million upfront consideration comprised $500 million received in 2021 and $200 million received in January 2022. Up to $1.5 billion in additional milestones may be payable, subject to development, regulatory, and commercial events.
- Alector and GSK share U.S. commercialization profits and losses equally and share development costs generally 40%/60% (Alector/GSK), with exceptions for initial Phase 2 costs and manufacturing development. Outside the U.S., GSK commercializes the programs and Alector may receive double-digit tiered royalties. GSK may terminate for convenience on 180 days’ notice.
- Management increased its forecast of total costs to satisfy collaboration performance obligations by 14% in 2021; the cumulative adjustment reduced recognized revenue by approximately $12.8 million. Revenue recognition depends on estimates of development costs and, for GSK license allocation, assumptions including forecasts, timelines, discount rates, and probabilities of success.
- Under the AbbVie collaboration, Alector recognized $14.9 million of revenue in 2021, down from $21.1 million in 2020, in part because estimated total program costs increased. AbbVie’s TREM2 and SIGLEC 3 programs remain subject to option and cost/profit-sharing terms.
Pipeline, outlook, and principal risks
- AL001: In a global pivotal Phase 3 trial for FTD-GRN; the Phase 2 open-label dataset showed normalized progranulin, stable or trending biomarkers, and results favorable to a matched historical control cohort. In up to 12 symptomatic patients at 12 months, management estimated 48% slower clinical progression; imaging analyses reported over 10% lower brain-atrophy rates and approximately 50% lower ventricular-enlargement rates versus matched controls. These are early, non-randomized comparisons, not confirmatory pivotal-trial results.
- AL002: In Phase 2 for early Alzheimer’s disease. ARIA were observed; most reported cases were asymptomatic and non-serious, but a small number of serious adverse events occurred among APOE e4/e4 homozygotes. Alector discontinued dosing of these participants and planned a protocol amendment to exclude them. The effect on enrollment timing was still being assessed; an independent monitoring committee reviews the study.
- AL101: Phase 1 interim data in healthy volunteers indicated progranulin increases in the periphery and brain lasting one month and general tolerability. Additional dose cohorts were underway, with data expected in 2022.
- AL003: Phase 1 data showed tolerability up to monthly intravenous doses of 15 mg/kg and target engagement. AL044 was expected to enter first-in-human testing in 2022. Alector also planned to advance oncology candidates AL008 and AL009 into clinical studies in 2022.
- Key risks include clinical failure or delay, uncertain safety and efficacy, ARIA, patient-enrollment challenges, reliance on collaborators and contract manufacturers, lack of long-term manufacturing supply agreements, competition, intellectual-property uncertainty, and potential effects of COVID-19 and inflation. Alector expects continued losses and may require additional financing. Its products remain unapproved and commercial revenue is uncertain.
- The company reported no material pending legal proceedings. Management and the auditor concluded internal control over financial reporting was effective as of December 31, 2021; the auditor issued unqualified opinions on the financial statements and internal controls.
Most important facts for investors to verify
- Progress, safety, enrollment, and eventual pivotal results for AL001 Phase 3, including how results compare with the non-randomized Phase 2 findings.
- Further ARIA updates, protocol changes, and enrollment consequences in the AL002 Phase 2 trial.
- Actual cash use and runway versus management’s mid-2024 estimate, including the timing and use of the January 2022 GSK payment.
- GSK and AbbVie collaboration milestones, cost-sharing obligations, revenue recognition estimates, and termination or opt-out provisions.
- Whether the 2022 clinical-development plans for AL044, AL008, and AL009 were achieved, and the costs and financing needs of advancing the broader pipeline.